Feature | January 13, 2010

January 13, 2010 – Research validates the efficacy of the recent reclassification of the T category in the International Association for the Study of Lung Cancer’s (IASLC) "Staging Manual in Thoracic Oncology" released in the January 2010 issue of the Journal of Thoracic Oncology.

In the sixth edition of the tumor, node and metastatis (TNM) staging system, there were no changes. Thus, the change in the seventh edition is significant as it is the first revision of TMN classification in lung cancer for 12 years, and represents the most drastic change there has been in the past 30 years.

The medical records of 1,393 patients with non-small cell lung cancer who underwent complete resection were thoroughly reviewed for pathologic findings and survival. The stage of all the patients was pathologically defined according to the present international staging system, previously revised in 1997. This study examined the relationship between the cut-off points of the tumor size for the new T category and the pathologic invasiveness

The TNM staging system is useful for both the clinical assessment of tumor progression and the determination of treatment plan, such as surgery, chemotherapy and radiation. In the forthcoming TNM classification, a revision with respect to lung cancer has been proposed by the International Association for the Study of Lung Cancer. The major revision is the T category, which makes an especially strict division by detailed cut points of tumor size (e.g., 2-, 3-, 5- and 7-cm). The proposed T revision has been determined and validated based on the overall survival date from a large international database.

The lead study author, Tokujiro Yano, M.D., called the new T classification, which is based mainly on the tumor size, “appropriate for the pathologic findings of the primary tumor.” The significant differences were observed among newly revised T subsets in at least one incidence of pathologic invasiveness, including lymphatic, vascular, or pleural invasion.

Past chair and author of the IASLC’s staging guide, Peter Goldstraw, added that IASLC will play a central role in the formation of future classification of TMN.

For more information: www.iaslcpubs.org/IASLC-Manual-Thoracic-print.html


Related Content

News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
News | Radiology Business

April 23, 2024 — A diverse writing group—lead by authors at the University of Toronto—have developed an approach for ...

Time April 23, 2024
arrow
News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Therapy

April 12, 2024 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery, and ...

Time April 12, 2024
arrow
News | Artificial Intelligence

April 9, 2024 —PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for ...

Time April 09, 2024
arrow
Subscribe Now